RBC Capital Maintains Outperform on Avid Bioservices, Lowers Price Target to $15
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Sean Dodge has maintained an Outperform rating on Avid Bioservices (NASDAQ:CDMO) but lowered the price target from $17 to $15.
September 08, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Avid Bioservices' price target has been lowered from $17 to $15 by RBC Capital, though the Outperform rating is maintained.
The news directly pertains to Avid Bioservices as RBC Capital has lowered its price target for the company. However, the Outperform rating is maintained, indicating that the analyst still expects the company to outperform the market. This could have a neutral impact on the stock price in the short term as the lowered price target might be offset by the maintained positive rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100